H.C. Wainwright Maintains Buy Rating and Raises Price Target for Tempus AI
Analyst Yi Chen of H.C. Wainwright maintained a buy rating on Tempus AI and increased the price target from $66 to $68.
Stocks · News reference
Tempus AI To Present Results From Study Evaluating AI-Enabled Pre-Screening Panel For Patients With Advanced Non-Small Cell Lung Cancer, At ESMO Congress 2026
Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology imagesTempus AI, Inc. (NASDAQ:TEM) today announced
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tempus AI Receives IVDR Certification for xR RNA Sequencing Assay
Tempus AI has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) for its xR assay, a Class C in vitro diagnostic device used for solid tumor profiling.
Tempus AI Expands Strategic Partnership with Bristol Myers Squibb and Pathos AI
Tempus AI has entered into multi-year agreements with Bristol Myers Squibb and Pathos AI, securing $192.5 million in total cash commitments to support oncology and neurological drug development.
Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio